In parallel, losartan shifts the immune landscape towards an immunostimulatory state, increasing CD8+ T cells, NK cells, and activated dendritic cells, while limiting Tregs and MDSCs, and may further sensitize tumor cells by suppressing IGF-1-mediated survival pathways. The gene discussed is IGF1; the disease is neoplasm.